Actively Recruiting
Whole Genome Sequencing Versus Whole Exome Sequencing for Congenital Diarrhea and Enteropahty
Led by Children's Hospital of Fudan University · Updated on 2026-03-24
180
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will seek to determine if whole genome sequencing (WGS) improves diagnostic rates, and outcomes for congenital diarrhea and enteropathy (CODE) patients. The investigator will enroll 180 patients in a randomized controlled study to either WGS or whole exome sequencing (WES). This study is designed to evaluate whether CODE patients would benefit from WGS guided precision medicine.
CONDITIONS
Official Title
Whole Genome Sequencing Versus Whole Exome Sequencing for Congenital Diarrhea and Enteropahty
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with chronic diarrhea lasting greater than 2 months
- Patients with consent from parents or legal guardians
- Biological relative of a patient enrolled in this study
You will not qualify if you...
- Chronic diarrhea caused by specific infections, such as CMV or Clostridioides difficile
- Chronic diarrhea with necrotizing enterocolitis or short bowel syndrome
- Functional diarrhea
- Patients with previously confirmed monogenic diarrhea
- Patients with poor compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ying Huang
Shanghai, Shanghai Municipality, China, 201102
Actively Recruiting
Research Team
Y
Ying Huang, MD, PhD
CONTACT
L
Lin Wang, MD,PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here